Literature DB >> 2982745

Capacity of B-lymphocytic lines of diverse tumor origin to produce and respond to B-cell growth factors: a progression model for B-cell lymphomagenesis.

J Gordon, P Aman, A Rosén, I Ernberg, B Ehlin-Henriksson, G Klein.   

Abstract

Human cell lines established from cases of acute lymphoblastic leukemia, lymphosarcoma, Burkitt's lymphoma and multiple myeloma and representing stages of B-lymphocyte development ranging from pre-B through to plasma cells, were assessed for their ability to produce and respond to B-cell growth factors (BCGF). All B-cell lines studied were found to be constitutive producers of a growth activity which assisted the S-phase entry of normal activated B-cells and provided growth support for lymphoblastoid cells transformed by Epstein-Barr virus. Furthermore, all lines responded by enhanced proliferation to supernatants from a BCGF-producing T-cell hybridoma. Not all lines, however, displayed autostimulation to their own supernatants and no tumor B-cell line appeared totally dependent on soluble factors for its growth. Non-tumorigenic B-cell lines, by contrast, revealed a strict dependency on homologous growth factor for their continued proliferation in suspension culture. The findings support a progression model of lymphomagenesis based upon the utilization, production and, ultimately, emancipation from growth-promoting soluble factors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982745     DOI: 10.1002/ijc.2910350218

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Growth of B95-8 cells and expression of Epstein-Barr virus lytic phase in serum-free medium.

Authors:  J E Shaw; R G Petit; K Leung
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells.

Authors:  A Calender; M Billaud; J P Aubry; J Banchereau; M Vuillaume; G M Lenoir
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus.

Authors:  D Liebowitz; D Wang; E Kieff
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

4.  EB virus induction is associated with B-cell maturation.

Authors:  D H Crawford; I Ando
Journal:  Immunology       Date:  1986-11       Impact factor: 7.397

5.  Requirements for growth of Epstein-Barr virus-transformed cells at low cell densities.

Authors:  R F Tiebout; R W Sauerwein; W G van der Meer; F van Boxtel-Oosterhof; W P Zeijlemaker
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

6.  Suppression of polyclonal B cell proliferation mediated by supernatants from human myeloma bone marrow cell cultures.

Authors:  D Peest; R Hölscher; R Weber; R Leo; H Deicher
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

7.  Response of neoplasms of B cell lineage to the proliferative effects of B cell growth factor and the phorbol ester TPA.

Authors:  M C Kinney; R D Collins; J Whitlock; J B Cousar; L B Vogler
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

8.  Defective expression of CD23 and autocrine growth-stimulation in Epstein-Barr virus (EBV)-transformed B cells from patients with Wiskott-Aldrich syndrome (WAS).

Authors:  H U Simon; E A Higgins; M Demetriou; A Datti; K A Siminovitch; J W Dennis
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

9.  Maintenance of growth transformation with Epstein-Barr virus is mediated by secretion of autocrine growth factors in two serum-free B-cell lines.

Authors:  J E Shaw; L A Baglia; K Leung
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

Review 10.  Malignant B-cells have receptors for and respond to interleukin-2.

Authors:  P Panayotides; R Lenkei; A Porwit; P Reizenstein
Journal:  Med Oncol Tumor Pharmacother       Date:  1986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.